BY ADRIAN P. NEMES III
Janssen, owned by the American Company Johnson & Johnson (J&J), is no longer recruiting volunteers for the third phase of the clinical trial of its Coronavirus 2019 vaccines in Bacolod City.
Dr. Adonis Guancia, principal investigator of J&J’s clinical trial, told the DAILY STAR that they are now finalizing their data and will continue to observe the individuals who were inoculated with the vaccines.
Guancia said he cannot divulge the data on how many have been inoculated but admitted that they have not reached their target number of volunteers yet.
Earlier, J&J announced that it is looking for 500 volunteers to participate in the trial adding that they will accept volunteers with high blood pressure, cancer, and diabetes, among others, as long as they are 40 years old and above.
Guancia noted that J&J will be rolling-out its vaccines soon although they do not know yet when the Bureau of Food and Drug Administration in the Philippines will issue the Emergency Use Authorization.
Asked if Bacolod will be prioritized, he said, that it will only be known once they are already given the go-signal to roll-out the vaccines.
The vaccines manufactured by Janssen, the same company that has developed vaccines for Ebola and constructed investigational Zika, respiratory syncytial virus (RSV), and HIV vaccines, is 85 percent effective, its website showed.
It added that the vaccines also showed protection against COVID-19 related hospitalization and death, beginning 28 days after vaccination.
In the Philippines, aside from Bacolod City, Janssen is conducting trials in La Paz District in Iloilo, Metro Manila, and Cabuyao and San Pablo cities in Laguna.*